Arbutus Biopharma Corp vs ACADIA PHARMACEUTICALS INC · latest fiscal year · computed from SEC XBRL filings
| Metric | ABUS | ACAD |
|---|---|---|
| Revenue | $14.1M | $1.07B |
| Revenue growth (YoY) | 128.2% | 11.9% |
| Operating margin | -271.0% | 9.8% |
| Net margin | -237.9% | 36.5% |
| FCF margin | -281.5% | 9.8% |
| Capex % of revenue | 0.0% | 0.4% |
Want ABUS against its full peer set, not just ACAD?
The CompsDesk pack: up to 12 peers you choose, up to 14 metrics (6 core guaranteed), trends for every filed year (up to five), a citation on every number — board-ready PDF + CSV, $249.
Green = better on that metric where direction is unambiguous. Source: SEC EDGAR XBRL (10-K). "n/a" = not disclosed under mapped tags; never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.